These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8999503)

  • 21. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia.
    Nakamura T; Scorilas A; Stephan C; Jung K; Soosaipillai AR; Diamandis EP
    Cancer Res; 2003 Oct; 63(19):6543-6. PubMed ID: 14559849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Total and free PSA: a methodical and clinical evaluation of five assays.
    Reiter W; Stieber P; Schmeller N; Nagel D; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1997; 17(6D):4759-65. PubMed ID: 9494603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Molecular forms of PSA and differentiating between benign hypertrophy,carcinoma, and disseminated prostatic carcinoma. Correlation between two determination technics].
    Sáez Lavilla C; Guallar Labrador A; Castrillo Rubio J; Allepuz Losa CA; Baringo Fuentes T; Ascaso Bandrés A; Navarro Izquierdo AL; Rioja Sanz LA
    Arch Esp Urol; 1999 May; 52(4):315-21. PubMed ID: 10380320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
    Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
    J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH.
    Abrahamsson PA; Kuriyama M
    Hinyokika Kiyo; 1998 Apr; 44(4):223-32. PubMed ID: 9617617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of free to total prostate specific antigen ratio in serum in the diagnosis of prostatic enlargement.
    Bhuiyan AK; Kibria SA; Subhan SS
    Bangladesh Med Res Counc Bull; 2004 Aug; 30(2):51-9. PubMed ID: 15813483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
    Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
    Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM
    Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
    Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
    Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Experience with prostate-specific antigen in patients with prostatic cancer].
    Romics I; Bach D
    Orv Hetil; 1989 Dec; 130(52):2797-800. PubMed ID: 2481833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate: which cutoff should be used?
    Lein M; Stephan C; Jung K; Schnorr D; Loening S
    Cancer Invest; 1998; 16(1):45-9. PubMed ID: 9474251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostatic cancer and BPH.
    Brown SA
    Postgrad Med; 1994 Jul; 96(1):24-5. PubMed ID: 7517542
    [No Abstract]   [Full Text] [Related]  

  • 35. [How should an elevated blood level of prostate-specific antigen be interpreted?].
    Boccon-Gibod L
    Rev Med Suisse Romande; 1992 Nov; 112(11):955-6. PubMed ID: 1281334
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluation of molecular species of prostate-specific antigen complexed with immunoglobulin M in prostate cancer and benign prostatic hyperplasia.
    Goč S; Janković M
    Dis Markers; 2013; 35(6):847-55. PubMed ID: 24367138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors.
    Hilz H; Noldus J; Hammerer P; Buck F; Lück M; Huland H
    Eur Urol; 1999 Oct; 36(4):286-92. PubMed ID: 10473986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia.
    Pretlow TG; Pretlow TP; Yang B; Kaetzel CS; Delmoro CM; Kamis SM; Bodner DR; Kursh E; Resnick MI; Bradley EL
    Int J Cancer; 1991 Nov; 49(5):645-9. PubMed ID: 1718912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prostate-specific antigen and prostatic cancer].
    Otnes B; Tveter KJ
    Tidsskr Nor Laegeforen; 1994 Mar; 114(7):829. PubMed ID: 7516585
    [No Abstract]   [Full Text] [Related]  

  • 40. Successful separation between benign prostatic hyperplasia and prostate cancer by measurement of free and complexed PSA.
    Lilja H; Stenman UH
    Cancer Treat Res; 1996; 88():93-101. PubMed ID: 9239474
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.